AbCellera Biologics to raise up to US $391M from NASDAQ IPO at up to US $4.52B valuation

AbCellera Biologics Inc. has filed a new amendement to Form S-1 Registration Statement with SEC in connection with its proposed initial public offering of common shares.

AbCellera Biologics Inc. will issue 23 million shares at an offering price of between US $14.00 and $17.00 per share. (all dollar figures in US dollars)

Immediately following the closing of the IPO, AbCellera Biologics will have 265,952,096 shares, valuing the company between $3.72 billion to $4.52 billion on a non-diluted basis before taking into account of any exercise of the over-allotment option granted.

Founded by Dr. Carl L. G. Hansen, Ph.D. and Dr. Véronique Lecault, Ph.D., Vancouver based AbCellera Biologics is a privately held technology company with an antibody discovery platform that searches, decodes, and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease.

AbCellera Biologics has raised over $172 million in equity and convertible debenture financings from investors including DCVC Bio, Viking Global Investors, OrbiMed, Baker Brothers, Peter Thiel/Founders Fund, Eli Lilly and Company, Harvard Management Private Equity Corporation, and the University of Minnesota.

Following the closing of the offering, Dr. Hansen, DCVC Bio, and Viking Global Investors, are the three largest shareholders controlling 61,202,750, 29,114,300 and 19,188,773 shares, with valuation of up to $1.04 billion, $495 million and $326 million respectively.

photo credit: AbCellera Biologics